Application of kaempferol in preparation of medicine for treating or improving cardiac injury

A technology of kaempferol and heart, which is applied in the field of medicine and can solve the problems of lack of drugs for treating cardiovascular complications

Pending Publication Date: 2021-04-09
ZHEJIANG CANCER HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no related use of kaempferol for improving heart function defects or cardiomyocyte apoptosis in this area.
[0004] In summary, there is still a lack of effective drugs for the treatment of cardiovascular complications caused by chemotherapy drugs in this field.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kaempferol in preparation of medicine for treating or improving cardiac injury
  • Application of kaempferol in preparation of medicine for treating or improving cardiac injury
  • Application of kaempferol in preparation of medicine for treating or improving cardiac injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Kaempferol alleviates cardiac hypertrophy and cardiac insufficiency caused by cisplatin

[0031] In order to investigate the protective effect of kaempferol on cisplatin-induced cardiac hypertrophy and cardiac insufficiency, the protective effect of kaempferol pretreatment on cisplatin-induced myocardial hypertrophy and cardiac insufficiency in mice. Subcutaneous injection of cisplatin (3 mg kg -1 ·2days-1 ) for one week to establish an animal model of cisplatin-induced cardiac injury, kaempferol (10 mg·kg -1 ·day -1 ) orally administered one week before the injection of cisplatin and continued for two weeks. In the control group, the same amount of cisplatin was subcutaneously injected, and the same amount of 1% CMC-Na vehicle was orally administered one week before the injection of cisplatin.

[0032] Ejection fraction and fractional shortening were measured by echocardiography, with results such as figure 1 As shown in A-B, the results showed that cispl...

Embodiment 2

[0035] Example 2 Kaempferol reduces cisplatin-induced cardiomyocyte apoptosis

[0036] In order to further explore the protective effect of kaempferol, we analyzed the apoptosis of cardiomyocytes in myocardial tissue. The specific steps are as follows:

[0037] 1. Sections were dewaxed in xylene, 100% ethanol, 90% ethanol, 80% ethanol, and 70 ethanol;

[0038] 2. Dilute 2 mg / mL Proteinase K solution with 0.3% Triton PBS at a ratio of 1:100 to make the final concentration 20 μg / mL; add 100 μL of 20 μg / mL Proteinase K solution dropwise to each sample to make It was completely covered and incubated at room temperature for 20 min;

[0039] 3. Rinse the sample 2-3 times with PBS solution, gently remove excess liquid, and carefully blot the liquid around the sample on the slide with filter paper;

[0040] 4. Dilute 5×Equilibration Buffer with deionized water at a ratio of 1:5, add 100 μL of 1×Equilibration Buffer dropwise to each sample to completely cover the area of ​​the sample...

Embodiment 3

[0044] Example 3 Kaempferol can significantly inhibit cisplatin-induced myocardial tissue inflammation

[0045] Subcutaneous injection of cisplatin (3 mg kg -1 ·2days -1 ) for one week to establish an animal model of cisplatin-induced cardiac injury, kaempferol (10 mg·kg -1 ·day -1 ) was administered orally one week before the injection of cisplatin and continued for two weeks. The control group was subcutaneously injected with the same amount of cisplatin, and the same amount of 1% CMC-NA vehicle was orally administered one week before the injection of cisplatin. The blank group was subcutaneously injected with the same volume of normal saline, and the same volume of 1% CMC-Na vehicle was orally administered one week before the injection of cisplatin.

[0046] The result is as image 3 shown in. Immunohistochemical staining showed that cisplatin increased the expression of CD68 in myocardial tissue, indicating an increased number of macrophages infiltrating myocardial t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of kaempferol in preparation of a medicine for treating or improving cardiac injury, and particularly provides an application of kaempferol in preparation of a medicine composition for treating cardiac injury or improving cardiac dysfunction, wherein the medicine composition can be used for treating cardiovascular complications caused by cancer chemotherapy medicines.

Description

technical field [0001] The invention relates to the field of medicine, and specifically, the invention provides the use of kaempferol for preparing a pharmaceutical composition for treating myocardial injury and cardiac insufficiency caused by chemotherapeutic drugs. Background technique [0002] Cardiovascular complications caused by cancer chemotherapy drugs have become a common problem in cancer treatment. Cisplatin is a platinum-based antitumor drug widely used in the treatment of various solid tumors such as the endometrium, neck, head, bladder, testis, ovary, kidney and lung. Although platinum-based chemotherapeutics are reliable and effective in cancer treatment, the side effects of cisplatin, such as neurotoxicity and cardiotoxicity, are a major obstacle to successful cancer treatment. Numerous studies have shown that cisplatin can increase plasma troponin I, creatine kinase and creatine kinase isoenzyme MB levels. In conclusion, cisplatin-induced cardiac injury ul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P9/00A61K33/243A61P35/00
CPCA61K31/352A61P9/00A61K33/243A61P35/00A61K2300/00
Inventor 戚雅君方罗付霜方琦璐袁晓红邹杰曹莹莹杨迪虹
Owner ZHEJIANG CANCER HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap